NERV
$7.54-0.53 (-6.57%)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Recent News
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of schizophrenia—an area where management has historically lagged behind treatments for positive sympto
Minerva Neurosciences: Q4 Earnings Snapshot
BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $283.7 million in its fourth quarter.
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most
Key Insights Minerva Neurosciences' significant individual investors ownership suggests that the key decisions are...
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia
Minerva Neurosciences (NASDAQ:NERV) hosted a virtual key opinion leader (KOL) event focused on its development candidate roluperidone for negative symptoms in schizophrenia, outlining the clinical rationale for targeting negative symptoms, the challenges of measuring them in trials, and an update on
Minerva Neurosciences: Q3 Earnings Snapshot
BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $2.7 million in its third quarter.